LifeVantage (NASDAQ:LFVN - Get Free Report) issued an update on its FY 2024 earnings guidance on Friday morning. The company provided earnings per share guidance of 0.570-0.670 for the period, compared to the consensus earnings per share estimate of 0.600. The company issued revenue guidance of $202.0 million-$205.0 million, compared to the consensus revenue estimate of $209.3 million.
LifeVantage Stock Performance
LFVN stock traded up $0.46 during midday trading on Friday, reaching $6.57. 23,933 shares of the company traded hands, compared to its average volume of 33,350. The firm has a market capitalization of $84.54 million, a price-to-earnings ratio of 28.57 and a beta of 0.80. LifeVantage has a 52-week low of $3.04 and a 52-week high of $8.69. The business has a 50 day moving average of $6.51 and a 200-day moving average of $6.38.
LifeVantage (NASDAQ:LFVN - Get Free Report) last issued its quarterly earnings results on Tuesday, January 30th. The company reported $0.10 earnings per share (EPS) for the quarter. LifeVantage had a return on equity of 19.96% and a net margin of 1.40%. The company had revenue of $51.62 million during the quarter.
LifeVantage Company Profile
(
Get Free Report)
LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care, bath and body, and targeted relief products. It offers Protandim, a dietary supplement; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 fatty acids, Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support gut health; PhysIQ, a weight management system; LifeVantage IC Bright, a supplement to support eye and brain health, reduce eye fatigue and strain, supports cognitive functions, and support normal sleep patterns; Petandim for Dogs, a supplement to combat oxidative stress in dogs; and Axio, a nootropic energy drink mix.
Read More
Before you consider LifeVantage, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and LifeVantage wasn't on the list.
While LifeVantage currently has a "hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
